OR Royalties (NYSE:OR) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

OR Royalties (NYSE:OR – Get Free Report) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Monday.

Several other analysts have also weighed in on the stock. Jefferies Financial Group reaffirmed a “hold” rating and set a $38.00 price objective on shares of OR Royalties in a report on Sunday, December 7th. Zacks Research lowered OR Royalties from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of OR Royalties in a report on Monday, December 29th. Canaccord Genuity Group upgraded OR Royalties from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. Finally, Scotiabank cut OR Royalties from an “outperform” rating to a “sector perform” rating and increased their target price for the stock from $33.00 to $41.00 in a report on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.75.

View Our Latest Research Report on OR

OR Royalties Price Performance

OR Royalties stock opened at $43.74 on Monday. The firm has a market capitalization of $8.19 billion, a P/E ratio of 55.36 and a beta of 0.78. The stock has a fifty day moving average price of $35.90 and a two-hundred day moving average price of $33.89. OR Royalties has a 52-week low of $17.55 and a 52-week high of $44.16.

OR Royalties (NYSE:OR – Get Free Report) last issued its earnings results on Wednesday, November 5th. The basic materials company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.19 by $0.03. The company had revenue of $71.63 million for the quarter, compared to the consensus estimate of $53.85 million. OR Royalties had a net margin of 60.72% and a return on equity of 10.67%. On average, equities research analysts predict that OR Royalties will post 0.62 EPS for the current fiscal year.

Institutional Trading of OR Royalties

Several institutional investors and hedge funds have recently added to or reduced their stakes in OR. Caitlin John LLC bought a new stake in shares of OR Royalties during the third quarter worth approximately $78,000. Eagle Global Advisors LLC acquired a new position in shares of OR Royalties in the 3rd quarter valued at $206,000. Merit Financial Group LLC acquired a new position in shares of OR Royalties in the 3rd quarter valued at $215,000. Flow Traders U.S. LLC bought a new position in shares of OR Royalties in the 3rd quarter worth $217,000. Finally, Moors & Cabot Inc. acquired a new stake in shares of OR Royalties during the third quarter worth $220,000. 68.52% of the stock is owned by institutional investors.

About OR Royalties

(Get Free Report)

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.

Featured Articles